NCT04321070View on ClinicalTrials.gov

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

December 14, 2019

Study Completion Date

March 6, 2020

Conditions
Acne Vulgaris
Interventions
DRUG

Clindamycin Phosphate

A thin film of investigation product will be applied to the affected areas of the face once daily

DRUG

Clindamycin Phosphate RLD

A thin film of investigation product will be applied to the affected areas of the face once daily

DRUG

Placebos

A thin film of investigation product will be applied to the affected areas of the face once daily

Trial Locations (1)

28217

Catawba Research LLC, Charlotte

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT04321070 - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter